Year 2022 / Volume 114 / Number 6
Editorial
Everolimus versus mycophenolate mofetil in liver transplantation: every improvement in renal function matters

312-313

DOI: 10.17235/reed.2022.8902/2022

Paolo De Simone, Jessica Bronzoni, Caterina Martinelli,

Abstract
The current edition of the journal features a Spanish, nationwide, multi-institutional study by Gomez Bravo MA et al. exploring the advantages of everolimus (EVR)-facilitated tacrolimus (TAC) minimization versus TAC in combination with mycophenolate mofetil (MMF) after liver transplantation (LT).
Share Button
New comment
Comments

21/06/2022 0:57:07
Am here to appreciate Dr.Timothy for using his herbal medicine to cure my Herpes virus. since 2016 i have been living with this virus and it has been giving me challenges, I was so perplexed cause i have been taking several drugs to be cured but all of my effort was in vain,one evening i was browsing through the internet then i saw several testimonies about Dr.Timothy curing people from Herpes virus and immediately i contacted his email address i told him about my sickness and he told me that i will be cured within 21 days he gave me some instructions and which i rightly followed. so he prepared a herbal medicine for me and sent it to me which i used for 21 days and everything was like a dream to me and my Herpes virus was totally gone why don't you contact Dr.Timothy he is very good and honest. contact him via email address; goodhealthherbalfoundation@yahoo.com OR website https://5dc41d5b6d60d.site123.me


References
1. Gomez Bravo MA, Prieto M, Navasa M, et al. Everolimus plus minimized tacrolimus on kidney function in liver transplantation: REDUCE, a prospective, randomized controlled study. Rev Esp Enf Dig 2022, in press.
2. De Simone P, Nevens F, De Carlis L, et al. Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. Am J Transplant 2012;12(11):3008-3020.
3. Jeng LB, Lee SG, Soin AS, et al. Efficacy and safety of everolimus with reduced tacrolimus in living-donor liver transplant recipients: 12-month results of a randomized multicenter study. Am J Transplant 2017;18(6):1435-1446.
4. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int, Suppl. 2013; 3: 1–150.
5. Allen AM, Kim WR, Therneau TM, et al. Chronic kidney disease and associated mortality after liver transplantation – a time-dependent analysis using measured glomerular filtration rate. J Hepatol 2014;61(2):286-92.
6. Fischer L, Klempnauer J, Beckebaum S, et al. A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation-PROTECT. Am J Transplant 2012;12(7):1855-1865.
7. Sterneck M, Kaiser GM, Heyne N, et al. Everolimus and early calcineurin inhibitor withdrawal: 3-year results from a randomized trial in liver transplantation. Am J Transplant 2014;14(3):701-710.
8. Sterneck M, Kaiser GM, Heyne N, et al. Long-term follow-up of five yr shows superior renal function with everolimus plus early calcineurin inhibitor withdrawal in the PROTECT randomized liver transplantation study. Clin Transplant 2016;30(6):741-748.
9. De Simone P, Carrai P, Coletti L, et al. Everolimus vs mycophenolate mofetil in combination with tacrolimus: a propensity score-matched analysis in liver transplantation. Transplant Proc 2018;50(10):3615-3620.
10. Tedesco-Silva H, Saliba F, Barten MJ, et al. An overview of the efficacy and safety of everolimus in adult solid organ transplant recipients. Transplant Rev (Orlando) 2022; 36(1):100655.
11. Lassailly G, Dumortier J, Saint-Marcoux F, et al. Real life experience of mycophenolate mofetil monotherapy in liver transplant patients. Clin Res Hepatol Gastroenterol 2021; 45(1):101451.
12. Norero B, Serrano CA, Sanchez-Fueyo A, et al. Conversion to mycophenolate mofetil monotherapy in liver recipients: Calcineurin inhibitor levels are key. Ann Hepatol 2017; 16(1):94-106.
13. Cruz CM, Pereira S, Gandara J, et al. Efficacy and safety of monotherapy with mycophenolate mofetil in liver transplantation patients with nephrotoxicity. Transplant Proc 2016; 48(7): 2341-3.
14. Holdaas H, De Simone P, Zuckermann A. Everolimus and malignancy after solid organ transplantation: A clinical update. J Transplant 2016; 2016:4349574.
15. Ferrín G, Guerrero M, Amado V, et al. Activation of mTOR signaling pathway in hepatocellular carcinoma. Int J Mol Sci 2020; 21(4):E1266.
Related articles

Digestive Diseases Image

Posterior reversible encephalopathy syndrome (PRES) in post liver transplantation

DOI: 10.17235/reed.2022.8694/2022

Letter

Ertapenem neurotoxicity in liver transplantation

DOI: 10.17235/reed.2021.8469/2021

Letter

EBVMCU in a liver-transplant patient

DOI: 10.17235/reed.2021.8064/2021

Digestive Diseases Image

Emphysematous hepatitis: a very rare entity with a poor prognosis

DOI: 10.17235/reed.2021.7795/2021

Digestive Diseases Image

Percutaneous treatment of a splenorenal shunt with an atrial septal closure device

DOI: 10.17235/reed.2020.7701/2020

Review

Physical frailty in liver transplantation

DOI: 10.17235/reed.2020.7448/2020

Letter

Management of hepatic artery aneurysms

DOI: 10.17235/reed.2020.7219/2020

Digestive Diseases Image

Epithelioid hemangioendothelioma: a rare cause of a liver tumor

DOI: 10.17235/reed.2020.7127/2020

Letter

Acute seronegative hepatitis C: two case reports

DOI: 10.17235/reed.2019.5921/2018

Letter to the Editor

Post-transplant lymphoproliferative disease after liver transplantation

DOI: 10.17235/reed.2017.5387/2017

Letter to the Editor

Liver metastasis from colorectal cancer 12 years after liver transplantation

DOI: 10.17235/reed.2017.4507/2016

Case Report

IBD or strongyloidiasis?

DOI: 10.17235/reed.2015.3847/2015

Citation tools
De Simone P, Bronzoni J, Martinelli C. Everolimus versus mycophenolate mofetil in liver transplantation: every improvement in renal function matters . 8902/2022


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 631 visits.
This article has been downloaded 194 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 02/05/2022

Accepted: 03/05/2022

Online First: 12/05/2022

Published: 07/06/2022

Article Online First time: 10 days

Article editing time: 36 days


Share
This article has been rated by 1 readers.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology